Apolipoproteins AI and B as therapeutic targets

Journal of Internal Medicine
Valentine Charlton-Menys, Paul N Durrington

Abstract

Currently the apolipoprotein B:AI ratio integrates information about the potential for cardiovascular disease (CVD) risk reduction better than any other lipid or lipoprotein index. Certainly it could, with benefit, replace serum cholesterol and HDL cholesterol in the estimation of CVD risk. Defining the therapeutic target of statin therapy in terms of serum apolipoprotein B (apo B) rather than LDL cholesterol could also help to optimize statin treatment. Deciding whether a therapeutic response is adequate also requires knowledge of whether there is persisting hypertriglyceridaemia, because this gives an indication of whether small dense LDL is likely to have been satisfactorily reduced. Raising low levels of HDL, probably best measured as apo AI, may also prove to be an important aim of treatment. This is, however, a more complex issue and also depends on the mechanism by which a particular therapy alters HDL levels and on whether the capacity of HDL to perform its anti-inflammatory and antioxidative functions is restored. A meta-analysis of randomized clinical trials of statins in which apo B and apo AI have been reported could provide valuable information.

References

May 29, 1975·The New England Journal of Medicine·F M SacksE H Kass
Aug 16, 1976·Clinica Chimica Acta; International Journal of Clinical Chemistry·P N DurringtonM Hartog
Jan 2, 1978·Clinica Chimica Acta; International Journal of Clinical Chemistry·P N DurringtonM Hartog
Jun 1, 1978·Metabolism: Clinical and Experimental·J BurslemJ P Miller
Dec 16, 1978·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
Dec 1, 1991·The Journal of Clinical Investigation·C J MannB E Bihain
Jan 1, 1991·Circulation·K M AndersonW B Kannel
Jan 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·N SakaiS Tarui
Mar 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·J de GraafA F Stalenhoef
May 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J GenestP Kwiterovich
Mar 20, 1986·The New England Journal of Medicine·S M Grundy
Jan 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A SnidermanP O Kwiterovich
May 21, 1980·Clinica Chimica Acta; International Journal of Clinical Chemistry·P N Durrington
Dec 1, 1982·Annals of Internal Medicine·A D SnidermanP O Kwiterovich
Aug 1, 1994·Atherosclerosis·A GawJ Shepherd
Dec 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·H LiN Maeda
Feb 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A ZambonJ D Brunzell
Feb 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·A GawJ Shepherd
May 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M J CaslakeJ Shepherd
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·P Barter
Sep 23, 2000·Nature·A J Lusis
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jul 27, 2001·The American Journal of Cardiology·C M BallantyneUNKNOWN ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study
Apr 16, 2002·European Journal of Clinical Investigation·B MacknessM I Mackness
Nov 12, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Philippa J TalmudSteve E Humphries
Feb 8, 2003·Atherosclerosis. Supplements·Paul Durrington
Jul 18, 2003·Clinica Chimica Acta; International Journal of Clinical Chemistry·Valentine C MenysPaul N Durrington

❮ Previous
Next ❯

Citations

Feb 26, 2009·Menopause : the Journal of the North American Menopause Society·Murat CelilogluTurkan Kolamaz
Jun 9, 2007·Current Opinion in Cardiology·Göran Walldius, Ingmar Jungner
Jul 8, 2011·Current Opinion in Lipidology·Handrean Soran, Paul N Durrington
Nov 6, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Tetsuo YamadaAkira Tanaka
May 23, 2007·Journal of Cardiac Failure·Grigorios Giamouzis, Javed Butler
Jan 16, 2007·Medical Hypotheses·Xian-sheng HuangYang-ping Luo
Jun 21, 2019·Current Opinion in Lipidology·Handrean SoranPaul N Durrington
May 26, 2020·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Haitham GalalMohamed Shehata

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.